Unlock stock picks and a broker-level newsfeed that powers Wall Street.

US Penny Stocks To Watch In February 2025

In This Article:

As the U.S. stock market navigates a mixed trading environment, with indices like the S&P 500 retreating slightly from record highs, investors are keeping an eye on smaller opportunities that might offer potential value. Penny stocks, though often associated with higher risk due to their smaller size and less-established nature, can still present intriguing investment possibilities when backed by strong financials and growth prospects. In light of current market conditions, we explore three penny stocks that stand out for their financial robustness and potential for long-term success.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.8625

$6.39M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$127.27M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.2698

$9.16M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.79

$84.63M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.4389

$46.53M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.46

$24.65M

★★★★★☆

PHX Minerals (NYSE:PHX)

$4.10

$154.8M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.89

$78.41M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.69

$383.33M

★★★★☆☆

Click here to see the full list of 708 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

GlycoMimetics

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: GlycoMimetics, Inc. is a biotechnology company focused on discovering and developing therapies for cancers and inflammatory diseases in the United States, with a market cap of $18.71 million.

Operations: GlycoMimetics, Inc. currently does not report any revenue segments.

Market Cap: $18.71M

GlycoMimetics, Inc., a biotechnology company with a market cap of US$18.71 million, is currently pre-revenue and faces significant challenges. The company reported a net loss of US$37.88 million for 2024, and its auditor expressed doubts about its ability to continue as a going concern. Recent executive departures coincide with plans for a merger with Crescent Biopharma, Inc., which may impact stability. GlycoMimetics has received an extension from Nasdaq to comply with listing requirements but risks delisting if it fails to meet the minimum bid price by June 2025. Despite being debt-free and having experienced leadership, financial uncertainties remain prominent factors for investors considering this penny stock.